Aytu BioPharma (NASDAQ:AYTU) Upgraded at Zacks Research

Aytu BioPharma (NASDAQ:AYTU) was upgraded by analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a report issued on Monday,Zacks.com reports.

A number of other equities analysts have also recently weighed in on the stock. Wall Street Zen upgraded shares of Aytu BioPharma to a “hold” rating in a research report on Saturday, February 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aytu BioPharma in a report on Wednesday, April 8th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $9.33.

Aytu BioPharma Stock Performance

AYTU opened at $2.30 on Monday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.16 and a quick ratio of 1.03. The firm has a fifty day moving average price of $2.59 and a 200 day moving average price of $2.44. Aytu BioPharma has a 1 year low of $1.26 and a 1 year high of $3.07. The stock has a market cap of $24.68 million, a P/E ratio of -0.60 and a beta of 0.28.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of AYTU. Dimensional Fund Advisors LP lifted its position in shares of Aytu BioPharma by 23.3% during the first quarter. Dimensional Fund Advisors LP now owns 43,585 shares of the company’s stock worth $119,000 after purchasing an additional 8,222 shares in the last quarter. XTX Topco Ltd purchased a new position in Aytu BioPharma in the fourth quarter valued at approximately $67,000. Diadema Partners LP increased its stake in Aytu BioPharma by 12.1% in the fourth quarter. Diadema Partners LP now owns 305,788 shares of the company’s stock valued at $795,000 after purchasing an additional 33,118 shares during the last quarter. Persistent Asset Partners Ltd increased its stake in Aytu BioPharma by 27.2% in the fourth quarter. Persistent Asset Partners Ltd now owns 79,415 shares of the company’s stock valued at $206,000 after purchasing an additional 16,963 shares during the last quarter. Finally, Rothschild Wealth LLC purchased a new position in Aytu BioPharma in the fourth quarter valued at approximately $52,000. Institutional investors and hedge funds own 33.49% of the company’s stock.

Aytu BioPharma Company Profile

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.

Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms.